The goal of this clinical trial is to evaluate the health effects of expanded hemodialysis in patients receiving hemodialysis. The main question it aims to answer is:
1\) Does expanded hemodialysis reduce the risk of death from any cause?
Researchers will compare expanded hemodialysis to conventional hemodialysis (the treatment currently used for the majority of patients receiving hemodialysis) to see if expanded hemodialysis works to improve patient outcomes.
Participants will continue to receive their regularly scheduled hemodialysis treatments using either a super high-flux/expanded dialysis filter or a high-flux/conventional dialysis filter. All other aspects of treatments remain the same. No additional tests or visits are required. Data will be obtained using administrative healthcare databases and medical record review (at a subset of participating locations).
Age 60 years or older; or
Age 45 to 59 years with a history of diabetes mellitus (Type 1 or Type 2) regardless of current glycemic status; and
Receiving any form of dialysis regularly for the previous 90 days; and
Currently receiving HD in-centre (main or satellite unit) 3 or more times per week; and
Known or anticipated intolerance to the Nipro Elisio HX dialyzer; or
Planned to receive HDF; or
Planned to receive nocturnal HD; or
Anticipated to discontinue in-centre HD in the next 3 months for any reason (examples: palliation, transplantation, home dialysis, recovery of kidney function, death, others); or
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead sponsor
Schulich School of Medicine and Dentistry
Collaborator
ICES
Collaborator
Nipro Canada Corporation
Collaborator
London Health Sciences Centre
Collaborator
Statistics Canada
Collaborator